Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer
about
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunity4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityImmunotherapy for brain cancer: recent progress and future promiseModulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancerImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsPro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic TargetsThe role of immune checkpoint inhibition in the treatment of ovarian cancer4-1BB agonism: adding the accelerator to cancer immunotherapyMinireview: Regulatory T Cells and Ovarian Cancer.Trial Watch: Toll-like receptor agonists in oncological indications.Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophagesMurine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophagesPD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.Ribonucleic acid (RNA) biosynthesis in human cancer.Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancerPeripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumorChronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusIL-27 induces the expression of IDO and PD-L1 in human cancer cells.Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression.CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpointImmunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
P2860
Q26738729-1EC3A1CF-5897-411C-BA69-F0C72E532293Q26769728-CD46DE2A-74D3-406B-A6EA-18C5F0EAFC63Q26779184-B8FB03D2-9914-4BC6-A3CC-010E1C8C226FQ26780387-B8C4CB83-E05D-4D3A-8971-71C194531A60Q26798047-335FCBA7-A028-4AB7-B2CB-36A6FC7F79B1Q26829847-4A6B358C-DAF5-416D-90C2-38B98163507CQ27012963-C393E74F-31AE-4D78-AE2F-BA297C2B42EDQ27015881-B37904AC-78CC-4C00-89B1-0C3055B5EBF8Q27022761-448523E5-407A-4267-8ABD-9EC88FE263B7Q28068378-B7D98CCE-7D2E-425A-9169-5ACB96ADFEDBQ28072532-E80E97C3-68A2-4F59-B789-13C3DBCE08D0Q28075712-E5C28ECE-4A7E-440B-A133-68C0CDE1FA70Q28076161-EBB392EB-6D8B-47CB-9AB1-3BFD5FE53002Q28077924-7E19BE95-70FE-40A8-81DD-E7CC0BA700A7Q28079622-0D025AEF-F64E-4352-B7F3-5BDD059C6A73Q30244214-59345244-4D63-488A-8218-0B6B07361189Q33878578-976DD740-2706-498E-8BF4-7D6F656313D5Q33898182-5105FE9C-4161-4CD9-91E4-5B8C2C92A038Q34044797-1F5C1A8A-BE0D-4690-9413-BA56DA949281Q34119854-5CCE6591-07D7-4EB5-8C39-22DE2FBDF966Q34644359-3FFFF8C9-4D14-43B1-B429-280E18DE0B56Q35107110-DBEEA85D-847C-4B0F-9D2B-BDDE59B2D7F2Q35527105-435C67CA-536B-4B7A-B7BD-4280485FE8CCQ35567989-047D67A6-D1CA-4B10-A8FD-A70708EFAD1CQ35623804-8BD16EC9-1F9D-4974-A8B7-CD5F0834D424Q35781562-19CAF756-127A-4B8A-B6EB-A26F6B0B70F5Q35798892-6182B08D-430B-4C88-8091-5F832B4632BBQ35984198-E77FDFE4-F186-4D9B-8ABC-9C326732B372Q36021225-B6C33880-AC55-4CE7-81C5-5F9289C77BB5Q36261405-0D094763-01A6-48E5-A463-2F14B1883A46Q36298565-C4C63A00-023A-4ABA-96F5-FD943E2A7381Q36528333-FD2F6A70-BEE4-4BF6-91D8-4BB54264B0CEQ36582785-DC1FD6A7-AA7D-4993-84AB-F4C410EC5041Q36685395-6C916D87-8D8F-44F2-8A11-5E723FE759C4Q36710977-41725A0C-3048-41BB-9375-4477976F87F4Q36738775-2F5BACB2-4905-4521-ABCE-B0CF603183E1Q36821069-8348694D-E57C-4648-B8B7-10B8196249D0Q36875531-D603DD4E-390F-446B-8218-8A0146732122Q36936564-04D932D6-32E7-4C04-B11C-18A64F0B1772Q37057942-3FECFDD4-A340-4DA6-9743-73E224EAE6E9
P2860
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic PD-1 pathway block ...... mune decline in ovarian cancer
@en
Therapeutic PD-1 pathway block ...... une decline in ovarian cancer.
@nl
type
label
Therapeutic PD-1 pathway block ...... mune decline in ovarian cancer
@en
Therapeutic PD-1 pathway block ...... une decline in ovarian cancer.
@nl
prefLabel
Therapeutic PD-1 pathway block ...... mune decline in ovarian cancer
@en
Therapeutic PD-1 pathway block ...... une decline in ovarian cancer.
@nl
P2093
P2860
P1433
P1476
Therapeutic PD-1 pathway block ...... mune decline in ovarian cancer
@en
P2093
George Coukos
Gordon J Freeman
Jaikumar Duraiswamy
P2860
P304
P356
10.1158/0008-5472.CAN-13-1550
P407
P577
2013-08-23T00:00:00Z